Calithera Biosciences Provides Update on Business Operations
14 avr. 2020 07h00 HE
|
Calithera Biosciences, Inc.
SOUTH SAN FRANCISCO, April 14, 2020 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical stage biotechnology company focused on discovering and developing novel small-molecule...
Calithera Biosciences Reports Fourth Quarter 2019 Financial Results and Recent Highlights
11 mars 2020 16h10 HE
|
Calithera Biosciences, Inc.
SOUTH SAN FRANCISCO, Calif., March 11, 2020 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical stage biotechnology company focused on discovering and developing novel small...
Calithera Biosciences to Report Fourth Quarter 2019 Financial Results on Wednesday, March 11, 2020
04 mars 2020 07h05 HE
|
Calithera Biosciences, Inc.
SOUTH SAN FRANCISCO, Calif., March 04, 2020 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage biotechnology company focused on discovering and developing novel small...
Calithera to Participate in the 9th Annual SVB Leerink Global Healthcare Conference
19 févr. 2020 07h05 HE
|
Calithera Biosciences, Inc.
SOUTH SAN FRANCISCO, Calif., Feb. 19, 2020 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical stage biotechnology company focused on discovering and developing novel small...
Calithera Biosciences Provides Overview of 2020 Corporate Milestones and Financial Guidance
13 janv. 2020 07h07 HE
|
Calithera Biosciences, Inc.
SOUTH SAN FRANCISCO, Calif., Jan. 13, 2020 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical stage biotechnology company focused on discovering and developing novel small...
Calithera Biosciences Announces New Employment Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
03 janv. 2020 07h05 HE
|
Calithera Biosciences, Inc.
SOUTH SAN FRANCISCO, Calif., Jan. 03, 2020 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical stage biotechnology company focused on discovering and developing novel small...
Data from Investigator-Sponsored Phase 2 Study of Calithera’s Telaglenastat with Azacitidine in Myelodysplastic Syndrome to be Presented at ASH Annual Meeting 2019
06 déc. 2019 07h05 HE
|
Calithera Biosciences, Inc.
SOUTH SAN FRANCISCO, Calif., Dec. 06, 2019 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical stage biotechnology company focused on discovering and developing novel small...
Calithera Biosciences Announces New Employment Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
05 déc. 2019 07h05 HE
|
Calithera Biosciences, Inc.
SOUTH SAN FRANCISCO, Calif., Dec. 05, 2019 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical stage biotechnology company focused on discovering and developing novel small...
Calithera Biosciences Reports Third Quarter 2019 Financial Results and Recent Highlights
12 nov. 2019 16h06 HE
|
Calithera Biosciences, Inc.
SOUTH SAN FRANCISCO, Calif., Nov. 12, 2019 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical stage biotechnology company focused on discovering and developing novel small...
Calithera to Present Preclinical Data from IL4I1 and CD73 Programs at the Society for Immunotherapy of Cancer (SITC) Annual Meeting
05 nov. 2019 08h01 HE
|
Calithera Biosciences, Inc.
- First presentation of preclinical data for newly-announced IL4I1 immuno-oncology program - Additional data demonstrate potential of CD73 inhibitor CB-708 to combine with immuno-oncology and...